Many trials exclude certain groups, and do so deliberately—children, for example, or people with physical or learning ...

Brand.com’s are connecting HCPs to information, with fewer hoops to jump through, courtesy of new digital tools promising to ...

This nation, and most of the world, recently marked five years since much of life as we knew it essentially shut down because ...

Overall, biopharma layoffs rose 3% last year compared to 2023, according to an analysis of yearly data. So ... light of weak durability and serious side effects, a move accompanied by a 50% ...

During his first term, Donald Trump’s skepticism toward science was well known, marked by his rejection of climate change ...

As an outbreak of measles infects hundreds of Americans, social media users are warning parents against the measles, mumps ...

A study has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails to offer ...

The "Inhalable Biologics Market Size, Share & Trends Analysis Report by Biologics (Peptides & Proteins, Monoclonal Antibodies ...

After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based ...

Moderna’s move into personalised cancer therapy ... mRNA-4157 heading for a pivotal phase 3 programme after a phase 2b data drop at ASCO. In the study, mRNA-4157 (V940) – which targets dozens ...

People who later experienced persistent shortness of breath or fatigue after a SARS-CoV-2 infection were already taking ...

Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% ...